Johnson & Johnson (JNJ)
Johnson & Johnson - Earlier use of CARVYKTI®demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Johnson & Johnson - Earlier use of CARVYKTI®demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak clinical signals • Minimal impact anticipated **Sentiment:** Neutral (50%) **Content type:** Clinical